Intra-Cellular Therapies Inc (STU:23I)
€ 81.5 2 (2.52%) Market Cap: 8.63 Bil Enterprise Value: 7.68 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 60/100

Intra-Cellular Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 05:20PM GMT
Release Date Price: €34.83 (+1.96%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Okay. Good afternoon, everyone. Welcome to the 1:20 session here on Day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover European and U.S. biopharmaceutical names for the firm. It's my great pleasure to be hosting Intra-Cellular Therapies today in a fireside chat session. And with that, from the company, we've got CEO, Sharon Mates; and Chief Commercialization Officer, Mark Neumann, joining us. Sharon and Mark, it's great to see you, both, welcome to the conference.

Sharon Mates
Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President

Thanks, Graig. It's a pleasure to be here.

Mark Neumann;Graig Suvannavejh
Intra-Cellular Therapies, Inc. - EVP & Chief Commercial Officer;Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Thank you, Graig.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot